ARGX Stock Analysis: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$851.29
-5.65 (-0.66%)
▼
5d:
-1.59%
30d:
-0.78%
90d:
+3.55%
HOLD
MODERATE Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Oct 22, 2026
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ARGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ARGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1925.82
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1195.78
28.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $851.29, which is considered slightly low relative to its 30-day fair value range of $849.28 to $893.84. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.5) compared to its historical average (27.3). Remarkably, the market is currently pricing in an annual earnings decline of 7.7% over the next few years. This pessimistic expectation contrasts with the company's recent 95.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ARGX is in a strong uptrend. The price is currently testing key support at $826.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1085.78 (+27.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ARGX is in a strong uptrend. The price is currently testing key support at $826.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1085.78 (+27.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$849.28 -
$893.84
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.5% below Wall St target ($1085.78)
- NEUTRAL: Bottoming setup forming (48/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$849.28 -
$893.84
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$826.45
Resistance Level
$894.03
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.52
Wall Street Target
$1085.78
(+27.5%)
Revenue Growth (YoY)
59.3%
Earnings Growth (YoY)
95.2%
Profit Margin
32.3%
Valuation Discount vs History
-7.7% cheaper
PE vs Historical
21.5 vs 27.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.7%
(market-implied from PE analysis)
1-Year Target
$785.74
(-8%)
2-Year Target
$725.24
(-15%)
3-Year Target
$669.40
(-21%)
3-Yr Target (if PE normalizes)
(PE: 22→27)
$849.17
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.5, Growth: 39.0%)
$2288.03
(+169%)
Base:
(SPY PE: 20.2, Growth: 39.0%)
$2150.85
(+153%)
Bear:
(PE: 17.2, Growth: 39.0%)
$1828.22
(+115%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Trailing PE: 32.66 | Current EPS (TTM): $26.24
Bull Case
$1421.05
(+67%)
Analyst growth 50.8%, PE expands to 35.9
Base Case
$1291.86
(+52%)
Market implied 50.8%, PE stable at 32.7
Bear Case
$582.72
(-32%)
Severe decline -20.0%, PE contracts to 27.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.5 to 27.3
Stabilization Target:
$1079.92
(+26.9%)
PE Expansion Potential:
+26.9%
Share & Embed Analysis
Last updated: August 16, 2026 3:02 AM ET
Data refreshes hourly during market hours. Next update: 4:02 AM
Data refreshes hourly during market hours. Next update: 4:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 41 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 49 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$140 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 55 HOLD |
|
SMMT
Summit Therapeutics PLC |
STRONG BUY
10 analysts |
$28 | 58 HOLD |
